Home Clinical Topics FDA approves new drug for rare form of rickets

FDA approves new drug for rare form of rickets

Author(s):

On April 17, the U.S. Food and Drug Administration (FDA) approved Crysvita (burosumab), the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia, a rare, inherited form of rickets.

Read more via FDA.

LEAVE A REPLY

Please enter your comment!
Please enter your name here